Post job

Meda in the US main competitors are Takeda Pharmaceuticals U.S.A., Inc., Daiichi Sankyo, and Eisai.

Competitor Summary. See how Meda in the US compares to its main competitors:

  • Takeda Pharmaceuticals U.S.A., Inc. has the most employees (30,481).
  • Employees at Takeda Pharmaceuticals U.S.A., Inc. earn more than most of the competitors, with an average yearly salary of $85,837.
Work at Meda in the US?
Share your experience

Meda in the US vs competitors

CompanyFounding dateZippia scoreHeadquarters# of LocationsRevenueEmployees
2001
4.7
Somerset, NJ1$80.0M149
1954
4.2
Saint Louis, MO1$40.0M50
2001
3.6
Herndon, VA1$4.3M125
2005
4.8
Parsippany-Troy Hills, NJ2$9.0B15,348
1987
4.4
Parsippany-Troy Hills, NJ1$22.0M350
2013
3.9
Roswell, GA1$5.0M222
1995
4.8
Woodcliff Lake, NJ2$5.3B1,864
1998
4.7
Deerfield, IL14$12.1B30,481
Nestlé Health Science-pamlab
-
3.5
Covington, LA1$250,00015
1928
4.3
Smyrna, GA3$5.7B7,600
-
4.5
--$6.4B158
2000
4.0
Cary, NC1$116.1M75
1996
4.5
San Diego, CA1$218.0M290
1996
3.8
Morristown, NJ1$146.1M171
2002
3.1
Ridgeland, MS1$4.3M25
2004
4.3
West Chester, PA1$8.6M71
1985
4.3
Fairfield, NJ1$145.0M300
2000
4.3
Newport, KY1$18.8M100
2011
3.9
Alpharetta, GA1$11.0M206
Odyssey Pharmaceuticals Inc
2000
3.7
East Hanover, NJ1$6.2M9
1995
4.0
Newark, CA2$342.7M494

Rate how well Meda in the US differentiates itself from its competitors.

Zippia waving zebra

Meda in the US salaries vs competitors

Among Meda in the US competitors, employees at Takeda Pharmaceuticals U.S.A., Inc. earn the most with an average yearly salary of $85,837.

Compare Meda in the US salaries vs competitors

CompanyAverage salaryHourly salarySalary score
Meda in the US
$71,187$34.22-
Forest Pharmaceuticals Inc
$73,116$35.15-
Ascend Therapeutics
$66,422$31.93-
Daiichi Sankyo
$82,543$39.68-
PDI
$64,390$30.96-
Sebela Pharmaceuticals
$63,740$30.64-

Compare Meda in the US job title salaries vs competitors

CompanyHighest salaryHourly salary
Meda in the US
$71,680$34.46
Forest Pharmaceuticals Inc
$78,691$37.83
Takeda Pharmaceuticals U.S.A., Inc.
$77,428$37.23
Eisai
$77,388$37.21
Avion Pharmaceuticals
$76,104$36.59
Organon
$75,535$36.32
Daiichi Sankyo
$75,293$36.20
Wraser Pharmaceutical
$74,554$35.84
PDI
$74,441$35.79
Santarus
$74,381$35.76
Aqua Pharmaceuticals
$73,824$35.49
Pernix Therapeutics Holdings
$73,345$35.26
Depomed
$73,246$35.21
Xanodyne Pharmaceuticals
$73,037$35.11
Sebela Pharmaceuticals
$73,033$35.11
Ascend Therapeutics
$72,834$35.02
UCB
$72,636$34.92
Odyssey Pharmaceuticals Inc
$72,586$34.90
Brad Pharm
$72,231$34.73
Nestlé Health Science-pamlab
$71,742$34.49

Do you work at Meda in the US?

Is Meda in the US able to compete effectively with similar companies?

Meda in the US jobs

Meda in the US demographics vs competitors

Compare gender at Meda in the US vs competitors

Job titleMaleFemale
PDI45%55%
UCB47%53%
Takeda Pharmaceuticals U.S.A., Inc.49%51%
Eisai50%50%
Daiichi Sankyo51%49%
Meda in the US--

Compare race at Meda in the US vs competitors

CompanyWhiteHispanic or LatinoBlack or African AmericanAsianUnknownDiversity score
60%15%11%10%4%
9.5
58%13%12%13%4%
9.7
61%13%11%12%4%
9.7
59%13%15%10%4%
9.8
64%13%13%7%3%
9.8
60%12%20%5%2%
6.8

Meda in the US and similar companies CEOs

CEOBio
Dan Peisert
Depomed

An intuitive leader who engenders a deep level of trust and loyalty while providing a clear vision and business strategy, with a proven track record in the pharmaceutical, generic, biotechnology and consumer product industries. Recognized for entrepreneurial leadership approach to turnaround and rapid growth environments, leveraging strategic creativity, consumer and professional customer insight, merger and acquisition experience and operational expertise, all driving shareholder value. Open to contract C-level and Board of Director positions.

Ken Keller
Daiichi Sankyo

Haruo Naito
Eisai

Haruo Naito is a Board Member at Eisai. He has worked as Director at Eisai, President/CEO at Eisai, and Executive Vice President at Eisai. Haruo works or has worked as CHAIRMAN at The Naiito Foundation. He attended Keio University and Northwestern University.

Gary D. Glick
Odyssey Pharmaceuticals Inc

Daniel Glassman
Brad Pharm

Jean-Christophe Tellier
UCB

Jean-Christophe Tellier joined UCB in 2011. He became UCB’s Chief Executive Officer on January 1, 2015 after having successfully led UCB’s BioBrands and Solutions division as Executive Vice President. He is a member of the Board of Directors of UCB, President of the Board of the European Federation of Pharmaceutical Associations (EFPIA), a member of the Board of PhRMA (Pharmaceutical Research and Manufacturers of America) and a member of the Board of WELBIO (Walloon Institute for Life Lead Sciences). Jean-Christophe Tellier is an experienced global leader. He was trained as a Medical Doctor and specialized in rheumatology. He has built a distinguished 30-year career in the biopharmaceutical industry, taking on different global leadership responsibilities in different parts of the world. His patient-centric approach, his passion for science, combined with his strategic and operational skills, have allowed him to significantly contribute to UCB’s success in recent years. For Jean-Christophe “engaging the patient in our vision is the best way for our company to be successful in the long term. Having a holistic view of a patient, of his/her life in his/her environment is essential to ensure effective treatment”. Jean-Christophe also believes that “all healthcare players - physicians, payors, carers, industry and academia - should cooperate even more effectively and become stronger partners sharing a same goal: improving patient care”. As a leader, Jean-Christophe has always had a passion for developing people, which he sees as “a key force to drive company success”. His ambition is to continue to further engage UCB teams behind the company’s vision and fully leverage UCB’s strong culture and talents

Jimmy Frangis
PDI

Kevin Ali
Organon

Meda in the US competitors FAQs

Search for jobs